Celmatix Offers Fresh Insight into Women’s ‘Biological Clock’ with New Discoveries

Next-generation women’s health company uncovers new understandings
around biomarkers that affect ovarian reserve

DENVER–(BUSINESS WIRE)–Today, Celmatix, the next-generation women’s health company, announced
the initial findings of two landmark research studies that shed new
light on biomarkers that are related to a woman’s fertility and her
ovarian reserve. These studies are among the largest ever aimed at
understanding ovarian reserve and its role in regulating the so-called
“biological clock.” Celmatix presented the findings during two
scientific sessions at the American Society of Reproductive Medicine
(ASRM) annual meeting this week in Denver, Colorado.

Over time, a woman’s ovarian reserve gradually depletes, and continues
to do so until menopause. It is generally accepted that a woman’s
fertility starts to decline more rapidly in her mid-30s, but in reality,
each woman’s experience is different. As more and more women across the
world wait until later in life to have children, it is becoming
increasingly critical for women to gain a deeper understanding of their
ovarian reserve and how it may impact their fertility. The new studies
presented this week by Celmatix are exemplary of this desperately needed
research.

The first study, Premature Menopause Genome-wide Association Study in
75,000 Women of European Ancestry
, conducted in collaboration with
personal genetics company 23andMe Inc, is the largest to date to examine
the genomic factors associated with premature menopause, a condition
that affects approximately one in 100 women. This case-control
genome-wide association study (GWAS) utilizing data from 75,000 23andMe
customers consented for research, confirmed an association between genes
involved in cellular quality control and a DNA damage checkpoint with
early menopause in women of European ancestry and suggested that many
loci associated with age of menopause are also associated with premature
menopause.

The second study, also the largest of its kind, Decreased Ovarian
Reserve Biomarkers are Associated with Reduced Fecundability in Women
with No History of Infertility
, established an association between
biomarkers including anti-Müllerian hormone (AMH), basal antral follicle
count (BAFC), and day three follicle-stimulating hormone (FSH) and
reduced fecundability in women seeking intrauterine insemination with
donor sperm (DIUI) as a proxy to the general population. In the wake of
recent studies questioning the utility of AMH testing as an indication
of future fertility in women without a history of infertility, these
initial findings shed new light on the complexity of the issue.

“For years, we’ve been at the precipice of a shift towards
consumer-driven scientific research, powered by the massive stores of
data volunteered through genetic testing or health-tracking apps,” said
Dr. Piraye Yurttas Beim, founder and CEO of Celmatix. “Until now, we
haven’t really seen the payoff in women’s reproductive health, but these
studies exemplify how that’s starting to change. With this new research,
we’re gaining unprecedented clarity into one of the most fundamental
factors affecting women’s fertility, and, as a result, offering women
and their doctors a more solid foundation from which to make informed
decisions about their care and family building.”

For more information on Celmatix and its research, visit www.celmatix.com/research.

About Celmatix Inc.

Celmatix is a next-generation women’s health company transforming
reproductive health care through genomics and big data. Founded in 2009
and based in New York City, Celmatix is disrupting how women approach
their lifelong fertility journey by empowering them and their physicians
with more personalized information. The company’s research-driven
products include the Fertilome® test, the world’s first multigene panel
test that reveals what a woman’s DNA says about her reproductive health,
Polaris®, a real-time predictive analytics platform in use at leading
fertility clinics across the U.S., which helps physicians optimize
patient outcomes and improve the patient experience, and MyFertility
Compass™, a data-driven education tool that gives women who are
currently trying to conceive insights into their fertility potential.

Contacts

Celmatix
Margaret Farrell, (203) 434-2240
m.farrell@celmatix.com

Leave a Reply

Sky Optics Media drone video